A drug discovery venture tackling next-generation cancer treatment using marine-derived compounds that improve tumor hypoxia while minimizing side effects. Already commercialized as veterinary medicine, it supports the lives of both humans and pets.
Our company provides stand-alone power supply systems powered by FLEXIINA®, a flexible thermoelectric generation module that efficiently recovers electricity from low-temperature waste heat below 300°C with superior cost performance. Utilizing this technology, we propose new business partnerships with our customers in areas such as kW-scale energy efficiency solutions and battery-free power for IoT devices.
A Kobe University-spinoff startup that creates useful chemicals—such as pharmaceutical and agricultural chemical raw materials and intermediates—by utilizing biogas (methane) derived from sewage, livestock manure, and food waste; chlorine produced by seawater electrolysis; and oxygen in the air for photoreactions.
A Globally Recognized Deep-Tech Company Developing Robotics and AI: We are a rare, cutting-edge technology venture based in Osaka, Japan, known for integrating robotics and AI to create customized solutions tailored to specific industry needs. Our technologies have been adopted by over 100 leading organizations across sectors such as construction, disaster response, infrastructure, railways, electric power, automotive, heavy industry, steel, maritime, and healthcare. Trusted for our problem-solving capabilities, we have earned a strong reputation across diverse industries. Prestigious institutions, including MIT, have visited us to study our advanced technologies.
The heart is an organ upon which life itself depends. With a commitment to providing new treatment options for heart failure and saving many lives, iHeart Japan is developing regenerative medicine products using iPS cells. Our product, IHJ-301, combines cells derived from iPS cells, including cardiomyocytes and endothelial cells, with a biomaterial, enabling long-term survival following implantation onto the heart and is expected to deliver strong therapeutic efficacy. Going forward, we plan to commercialize this product in Japan and internationally, with the aim of realizing a society in which patients can be saved without heart transplantation.
